<DOC>
	<DOCNO>NCT02572375</DOCNO>
	<brief_summary>The objective pivotal study : 1. evaluate bioavailability extended-release immediate release Codeine Phosphate/Guaifenesin tablet steady state follow multiple oral administration 2. assess safety tolerability Codeine Phosphate/Guaifenesin extend release formulation .</brief_summary>
	<brief_title>Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study</brief_title>
	<detailed_description>This study single-center , Two-site open-label , randomize , multiple-dose , two-treatment , two-period crossover design . During course study , thirty eight ( 38 ) healthy adult volunteer receive multiple dos Codeine Phosphate/ Guaifenesin extended-release tablet 30 mg/600 mg multiple dos IR Codeine Phosphate/ Guaifenesin immediate-release tablet 20 mg/400 mg tablet two separate treatment period . Volunteers enter clinic day prior [ approximately 12 hour ] dose confine clinic 7 night treatment period . The extended release tablet ( test ) administer two tablet two time day , 12 hour apart , immediate release tablet ( reference ) administer one tablet six time day , 4 hour apart . Pre-dose blood sample collect prior morning dose Days 1 , 2 , 3 , 4 , 5 , 6 7 . On Day 7 , Two extend release tablet give morning immediate release tablet give three time , morning 4 8 hour later . Serial blood sample collect Day 7 12 hour post morning dose . On Day 7 volunteer release study site 12-hour blood collection clinically appropriate return study site start next treatment minimum 7 day wash-out period , begin morning last dose take previous Period .</detailed_description>
	<mesh_term>Codeine</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine , phenylpropanolamine drug combination</mesh_term>
	<criteria>Healthy nonsmoking volunteer ( Female volunteer stable contraceptive medication regimen ( &gt; 3 month ) may continue course study use must document ) , 18 45 year age , inclusive ; Ethnic Group : Arab &amp; Mediterranean . Race : Mixed skin ( white &amp; black skin people ) . Body Mass Index ( BMI ) 18 32 kg/m2 , inclusive ( minimum 50 kg weight ) ; willing able comply appropriate instruction necessary complete study , ; Fully inform risk enter study willing provide write informed consent . Subject available whole study period give write informed consent If female , must practice abstinence use medically acceptable form contraception ( e.g. , intrauterine device , hormonal birth control [ continuously use least 3 month first dose ] , double barrier method ) . For purpose study , female consider childbearing potential unless post menopausal , biologically sterile , surgically sterile ( i.e. , hysterectomy , bilateral oophorectomy , tubal ligation ) one ( 1 ) year Normal Physical examination . Vital sign within normal range . All laboratory screening result within normal range , assess clinically Nonsignificant attend physician . Normal Kidney Liver function test . â€¢ Women childbearing potential n't use contraceptive method , pregnant and/or lactate woman . Ethnic Group ( Non Arab &amp; / Non Mediterranean ) A significant abnormality prestudy physical examination would place volunteer risk participation trial ; A clinical laboratory test value outside accepted reference range deem Investigator clinically significant ; Require prescription medication regular basis ; A clinically significant illness 28 day prior Period 1 dosing ( determined Investigator ) ; History serious illness impact fate drug History gastrointestinal obstruction , constipation , inflammatory bowel disease , gallbladder disease , pancreas disorder last 2 year , recent ( last 3 year ) gastrointestinal tract surgery , include gall bladder resection ; Known history presence cardiac , pulmonary , endocrine , musculoskeletal , neurological , hematological disease . Subjects acute pulmonary insufficiency , respiratory depression , acute chronic severe respiratory insufficiency history History head injury , seizures last 4 year deem Investigator clinically significant ; Mental disease History kidney disease urination problem last 2 year deem Investigator clinically significant Subjects renal and/or hepatic insufficiency exclude Presence significant physical organ abnormality History low blood pressure deem Investigator clinically significant ; A positive Hepatitis B surface antigen , Hepatitis C antibody screen , reactive HIV antibody screen ; Known suspect hypersensitivity , allergy , contraindication Codeine relate opioid and/or Guaifenesin ; History severe allergy allergic reaction study drug relate drug heparin Known history presence food allergy , condition know interfere absorption , distribution , metabolism excretion drug Known suspected history drug abuse within lifetime judge Investigator ; History alcohol abuse excessive intake alcohol within last 5 year judge Investigator ; Positive screen drug abuse , alcohol , cotinine ( nicotine ) screen admission unit prior administration investigational product ; Use drug induce inhibit hepatic metabolizing cytochrome P450 2D6 enzyme , within 30 day prior administration study formulation . Examples inducer include : piperidins , carbamazepine , dexamethasone , rifampin . Examples inhibitor include : cimetidine , diphenhydramine , fluvastatine , methadone , ranitidine ; Use prescription medication within 21 day OTC medication ( include vitamin herbal product ) within 7 day ( exclude flu vaccination ) prior first administration study medication without Sponsor approval ; Intake Alcohol 48 study drug administration , caffeine , xanthine beverages 24 hr study drug administration . Use investigational drug within 30 day prior first dosing ; Use tobaccocontaining product within 6 month first dose ; Donated 400 mL blood within 4 week first dose ; Participation another bioequivalence study and/or Clinical trial within 80 day prior start study Period I Exhausting physical exercise last 48 hour ( e.g . weight lift ) recent significant change dietary exercise habit . Abnormal vital sign Abnormal Kidney Liver function test . In opinion Investigator , unlikely unable successfully complete study ; Volunteer vegetarian . Vomiting , Diarrhea admission .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>